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c-CBL E3 Ubiquitin Ligase Is Overexpressed in
Cutaneous T-Cell Lymphoma: Its Inhibition Promotes
Activation-Induced Cell Death
Jianqiang Wu1, Katrin A. Salva1 and Gary S. Wood1
Mycosis fungoides and Se´zary syndrome are two major forms of cutaneous T–cell lymphoma (CTCL)
characterized by resistance to apoptosis. A central pathway for T-cell apoptosis is activation-induced cell death,
which is triggered through the T-cell receptor (TCR). This results in upregulation of FAS ligand (FASL) and
subsequent apoptosis through the FAS death receptor pathway. It has been known for more than a decade that
TCR signaling is defective in CTCL; however, the underlying mechanism has not been apparent. In this report, we
show that the E3 ubiquitin ligase, c-CBL, is overexpressed in CTCL and that its knockdown overcomes defective
TCR signaling, resulting in phosphorylation of PLC-g1, calcium influx, ROS generation, upregulation of FASL, and
extrinsic pathway apoptosis in CTCL cells expressing adequate FAS. In CTCL cells with suboptimal FAS
expression, FAS can be upregulated epigenetically by derepression of the FAS promoter using methotrexate,
which we showed previously has activity as a DNA methylation inhibitor. Using these combined strategies, FAS-
low as well as FAS-high CTCL cells can be killed effectively.
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INTRODUCTION
In this study, we use the term CTCL to refer specifically to
mycosis fungoides (MF)/Se´zary syndrome (SS) (Olsen et al.,
2011). On the basis of a variety of phenotypic, genetic, and
functional investigations, there is ample evidence that
cutaneous T-cell lymphoma (CTCL) is characterized by
resistance to apoptosis (Meech et al., 2001; Braun et al.,
2007; Contassot et al., 2008; Klemke et al., 2009; Wu et al.,
2009; Wu and Wood., 2011; Stutz et al., 2012; Wu and
Wood., 2014). CTCL cells often express only low levels of
extrinsic apoptotic pathway death receptors such as FAS and
are less responsive to apoptotic triggers compared with normal
T cells. Activation-induced cell death (AICD) is a key pathway
for apoptosis among CD4þ /CD45ROþ memory T cells, the
subset from which both MF (effector memory differentiation)
and SS (central memory differentiation) are derived. Following
short-term antigenic T-cell receptor (TCR) stimulation of
normal CD4þ T cells, FAS is upregulated but FAS ligand
(FASL) is not. The activated T cells are deleted by a passive
form of intrinsic (the mitochondrial pathway) apoptosis
triggered by IL-2 withdrawal following antigen clearance. In
contrast, chronic TCR stimulation normally results in
upregulation of both FAS and FASL with subsequent AICD
involving the extrinsic FAS death receptor pathway. For several
years, it has been recognized that TCR signaling is defective in
CTCL such that AICD is impeded (Fargnoli et al., 1997; Meech
et al., 2001; Klemke et al., 2009). It has been observed that
TCR-associated Y kinases are not properly activated upon TCR
engagement and that downstream signaling eventuating in
FASL upregulation does not occur. Nevertheless, an underlying
mechanism for these defects has not been elucidated.
One factor that regulates TCR signaling is c-CBL, a member
of the Casitas B-lineage Lymphoma protein family and a ring-
type E3 ubiquitin ligase that dampens TCR function by
interacting with TCR-associated Y kinases and promoting their
degradation (Schmidt and Dikic, 2005; Swaminathan and
Tsygankov, 2006; Loeser and Penninger, 2007; Paolino and
Penninger, 2010; Qiao et al., 2013). The TCR is expressed on
the cell surface in association with CD3 proteins to form the
TCR/CD3 complex. During AICD, engagement of TCR/CD3
normally leads to activation of proximate Y kinases and a
subsequent downstream cascade involving phosphorylation of
phospholipase C gamma-1 (PLC-g1), calcium mobilization,
generation of reactive oxygen species (ROS), and FASL
upregulation (Klemke et al., 2009).
In this report, we show that c-CBL is overexpressed in CTCL
and that its knockdown restores signaling through PLC-g1,
leading to upregulation of FASL and apoptosis in CTCL cells
that express adequate FAS. In CTCL cells with low FAS expres-
sion (a common MF/SS phenotype), FAS can be upregulated
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epigenetically by derepression of the FAS promoter using
methotrexate (MTX). We showed previously that in addition to
its role as an S-phase inhibitor that blocks purine synthesis,
MTX has activity as a DNA methylation inhibitor by blocking
the synthesis of S-adenosylmethionine, the principal methyl
donor for DNA methyltransferases (Wu and Wood, 2011).
Using these combined strategies to modulate both FAS and
FASL, FAS-low as well as FAS-high CTCL cells can be killed
effectively.
RESULTS
c-CBL protein and transcript are overexpressed in CTCL
In order to assess cellular levels of c-CBL protein and messenger
RNA, we analyzed CTCL cells using immunoblotting and
quantitative real-time reverse-transcriptase–PCR (QRT-PCR),
respectively. As shown in Figure 1a and b and Supplementary
Figure 1a online, compared with normal CD4þ
T cells in blood, baseline c-CBL protein and transcript were
increased more than 3-fold in all five CTCL lines derived from
patients with MF (MyLa, HH) or SS (SeAx, Hut-78, SZ4).
Among leukemic cells from SS patients, c-CBL protein and
transcript were increased more than 3-fold in 10/14 and 7/10
cases, respectively, with good correlation between individual
protein and transcript levels. Lesional skin biopsies (10 patch/
plaque MF, 3 tumor MF, 2 SS) were assessed by quantitative
multispectral image analysis of immunoperoxidase-stained
paraffin sections. Relative to reactive tonsil controls, c-CBL
expression was 3-fold greater in the CTCL specimens, regard-
less of lesion type (Supplementary Figure 1b and c online).
c-CBL knockdown induces upregulation of FASL
Given the frequently high expression of c-CBL in CTCL, we
next explored the effects of reducing c-CBL on the expression
of FASL. As shown in Figure 1c, we were able to significantly
decrease c-CBL protein expression in CTCL lines using short
interfering RNA (siRNA) technology. As shown by flow
cytometry in Figure 1d, this resulted in a significant increase
in FASL expression by CTCL lines and leukemic cells from two
SS patients (P1 and P2).
c-CBL knockdown induces apoptosis in CTCL cells that is
enhanced by MTX
We determined the impact of c-CBL knockdown–induced FASL
upregulation on apoptosis in CTCL lines and leukemic tumor
cells from two SS patients using Annexin V/propidium iodide
(PI) flow cytometry. Controls included isotype antibody, no
treatment, and nonsense siRNA. As shown in Figure 2a,
Annexin V–positive apoptotic cells (the two right-hand quad-
rants in each plot) increased markedly from the 3 to 9% range
with nonsense siRNA to the 37–98% range with c-CBL siRNA.
MTX upregulates FAS expression epigenetically by inhibit-
ing promoter methylation and derepressing FAS expression
(Wu and Wood, 2011). As shown in Figure 2a, when MTX
was combined with c-CBL siRNA knockdown, apoptosis was
increased to the 81–99% range. The impact of c-CBL siRNA
alone versus MTX plus c-CBL siRNA was less in MyLa (97 vs.
99%) and Hut-78 (98 vs. 99%) compared with HH (63 vs.
89%) and SZ4 (57 vs. 99%) because MyLa and Hut-78 have
lower promoter methylation and higher baseline FAS expres-
sion compared with HH and SZ4 (Wu et al., 2009; Wu et al.,
2011; Wu and Wood, 2011). In regard to potential clinical
relevance, the impact of combination therapy was 42-fold in
the SS leukemic cells in which apoptosis increased from 37 to
81% (P1) and from 41 to 98% (P2).
We determined the effect of MTX on c-CBL expression by
QRT-PCR and could detect no significant difference in c-CBL
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Figure 1. c-CBL is overexpressed in CTCL, and its inhibition induces FASL upregulation. (a) c-CBL protein. Grouped immunoblots show that, relative to the
highest expression among normal CD4þ blood T cells (N1, N2), all five cutaneous T-cell lymphoma (CTCL) lines and 7/10 Se´zary syndrome (SS) blood samples
(P1,2,5-8,10) expressed more than 3-fold greater c-CBL protein levels, as assessed by scanning densitometry. Numbers in the immunoblots refer to fold differences
in normalized c-CBL protein levels relative to control CD4þ T cells. MyLa (ML), Hut-78 (Hut), HH (H), SZ4 (SZ), and SeAx (Se). GAPDH is the loading control. (b)
c-CBL messenger RNA. Quantitative real-time reverse-transcriptase–PCR shows that, relative to normal CD4þ blood T cells pooled from three donors (N), all five
CTCL lines and the same 7/10 SS blood samples (P1,2,5-8,10) expressed more than 3-fold greater c-CBL transcript levels. *Po0.05; **Po0.01 in triplicate samples.
(c) Grouped immunoblots show effective knockdown of c-CBL in CTCL lines using short interfering RNA (siRNA) (þ ) relative to nonspecific siRNA ( ). GAPDH
is the loading control. (d) Flow cytometric histogram of mean fluorescence intensities (MFIs) shows marked upregulation of FASL expression (y-axis) induced by
c-CBL knockdown in CTCL lines and SS leukemic blood samples (P1, P2). Bars represent isotype control (white), no treatment (striped), nonsense siRNA (NS
siRNA; gray), and c-CBL siRNA (black). *Po0.05; **Po0.01 for c-CBL siRNA relative to NS siRNA controls in triplicate samples.
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transcript levels among five CTCL cell lines or three SS
leukemic blood samples. These findings were confirmed by
only minimal reductions in c-CBL protein levels detected by
immunoblotting in three CTCL lines (Supplementary Figure 2
online). These data are consistent with our other evidence that
MTX enhances apoptosis induced by c-CBL knockdown
mainly by increasing FAS, which is then available to interact
with the increased FASL resulting from c-CBL knockdown.
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Figure 2. c-CBL inhibition induces apoptosis in CTCL, and MTX enhances this effect. (a) Annexin V/propidium iodide flow cytometric dot plots show marked
induction of apoptosis (right two quadrants of each panel) after c-CBL knockdown. In cutaneous T-cell lymphoma (CTCL) lines (MyLa, Hut-78), which express high
baseline FAS death receptor, the effect is maximal with c-CBL knockdown alone. In the other samples, treatment with methotrexate (MTX) (which upregulates low
baseline FAS death receptor expression) enhances the effect of c-CBL knockdown in CTCL lines (HH, SZ4) and Se´zary syndrome leukemic blood samples (P1, P2).
(A) Nonsense short interfering RNA (NS siRNA), (B) MTX, (C) c-CBL siRNA, and (D) MTX plus c-CBL siRNA. Results are representative of triplicate experiments. (b)
MyLa and Hut-78 CTCL lines show marked apoptosis after c-CBL siRNA knockdown regardless of whether cells are treated with anti-CD3/CD28 antibodies (CDþ
vs. CD ) but are insensitive to antibody treatment alone. In contrast, normal CD4þ blood T cells (N) are sensitive to antibody treatment alone as well as c-CBL
knockdown. (A) and (C) NS siRNA and (B) and (D) c-CBL siRNA. Results are representative of duplicate experiments.
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Impact of antibody pretreatment on c-CBL knockdown in CTCL
and normal T cells
We determined whether treatment with anti-CD3 and anti-
CD28 antibodies was required to induce apoptosis in FAS-
high CTCL lines and normal CD4þ T cells subjected to c-CBL
siRNA knockdown. Representative findings are shown in
Figure 2b. CTCL cells were resistant to CD3/CD28 stimulation
(3–4% apoptosis with nonsense siRNA control), whereas
normal T cells were much more sensitive (71% apoptosis).
In contrast, CTCL cells were more sensitive to c-CBL siRNA
knockdown in the absence of CD3/CD28 stimulation (97–
98%) than were normal T cells (68%). This was also reflected
in the pace of apoptosis. After 96 hours of knockdown, CTCL
cells had more Annexin V/PI double-positive, late apoptotic
cells in the right upper quadrant of each panel (72–86%) than
did normal T cells (50%).
Apoptosis induced by c-CBL knockdown is mediated by the FAS
pathway
Given the fact that c-CBL knockdown significantly increased
FASL expression (Figure 1d), we suspected that the associated
increase in apoptosis (Figure 2) was due to extrinsic pathway
apoptosis. As shown in Figure 3a, cleaved caspase 8 was
significantly increased in multiple CTCL lines and SS leukemic
cells as assessed by flow cytometry. Simultaneous measure-
ment of cleaved caspase 9 using flow cytometry showed
minimal or no increases (data not shown). These caspase 8
and 9 findings were confirmed by western blotting in MyLa
and HH (Figure 3b). This is consistent with activation of the
extrinsic rather than intrinsic (mitochondrial) apoptotic path-
way (Stutz et al., 2012). Several families of death receptors
(e.g. FAS, TRAIL, tumor necrosis factor) can contribute to the
generation of cleaved caspase 8 via the extrinsic apoptotic
pathway. To determine the specific role of the FAS pathway in
apoptosis induced by c-CBL knockdown and MTX, we tested
the SeAx CTCL line. SeAx is FAS null because it lacks FAS
genes (Wu et al., 2011); yet, it does express TRAIL death
receptors (Braun et al., 2007). As shown in Figure 3c, FAS
expression remained undetectable, and apoptosis was low (1–
10%) under all conditions, despite a marked increase in FASL
expression. These findings indicate that c-CBL knockdown is
not cytotoxic generally and that the marked extrinsic pathway
apoptosis it typically induces in CTCL cells in association with
FASL upregulation probably requires expression of the FAS
death receptor. This is also supported by our prior studies
showing that when SeAx cells are transfected with a FAS
expression vector they are readily killed by exogenous FASL
(Wu et al., 2009).
c-CBL knockdown enhances signaling downstream of the TCR
that results in FASL upregulation
There are several known steps in the signaling cascade that
link TCR engagement to FASL upregulation. These include
phosphorylation of PLC-g1 at Tyr783, calcium ion influx, and
generation of ROS. We used immunoblotting and flow
cytometry to determine the effects of c-CBL knockdown on
these parameters. As shown in Figure 3d, siRNA knockdown
of c-CBL increased PLC-g1 phosphorylation in all four CTCL
lines tested. This increase was confirmed by western blotting
in these four cell lines and primary tumor blood samples from
three SS patients (Figure 3e). The phospho-PLC-g1/total
PLCg1ratio increased by 2–8-fold (median 4-fold). Similarly,
induction of calcium ion influx (Figure 3f) and ROS (Figure 3g)
also occurred in all four CTCL lines and tumor cells from all
three SS cases tested, as assessed by Fluo-4-AM flow cyto-
metry and 20,70-dichlorofluorescein diacetate (DCFDA) flow
cytometry, respectively.
DISCUSSION
FAS expression in T cells is inducible by a wide variety of
stimuli including MTX (Wu and Wood, 2011); however,
expression of FASL is tightly controlled (Meech et al., 2001),
and, as shown in this report and elsewhere, CTCL cells
generally express only very low levels of it (Wu et al., 2009;
Stutz et al., 2012). Therefore, our current findings provide an
approach for the upregulation of this missing trigger for the
FAS apoptotic pathway. In this study, we showed that the E3
ubiquitin ligase, c-CBL, is often overexpressed in CTCL at both
the protein and messenger RNA levels. This suggests a trans-
criptional regulatory defect, although the specific etiology of
c-CBL dysregulation remains to be determined. Known muta-
tions of CBL proteins are believed to reduce rather than
enhance the ubiquitin-mediated downregulation of activated
protein Y kinases. These kinases are then available to drive
cell proliferation and promote neoplastic transformation (Saito
et al., 2012). The distribution of germline and somatic
mutations are similar and cluster in the linker or ring finger
domains. Germline and/or somatic mutations have been
reported in chronic myelomonocytic, juvenile myelomono-
cytic, and acute lymphoblastic leukemias as well as in lung
cancers (Lo et al., 2011). CBL mutations can activate the RAS
pathway. Patients with germline CBL mutations have been
grouped together with those diagnosed as Noonan syndrome
and related disorders under the umbrella of so-called
‘‘RASopathies’’.
Consistent with the known function of c-CBL in the degra-
dation of receptor-associated Y kinases (Loeser and Penninger,
2007; Paolino and Penninger, 2010; Qiao et al., 2013), we
considered the possibility that some neoplasms might exhibit
enhanced rather than diminished c-CBL function. Specifically,
we postulated that c-CBL hyperactivity might help explain
the long-recognized defective TCR signaling characteristic of
CTCL cells (Fargnoli et al., 1997; Meech et al., 2001; Klemke
et al., 2009). Furthermore, given the importance of intact TCR
signal transduction to the induction of FASL during AICD, we
also postulated that the c-CBL abnormalities might have a
central role in the well-known resistance of CTCL cells to
apoptosis.
Our data support these hypotheses as depicted in Figure 3h.
Knockdown of c-CBL using siRNA technology resulted in
major increases in FASL expression among all CTCL cells
tested. Several hallmarks of TCR-mediated signal transduction
that lead to FASL upregulation were also enhanced. These
included PLC-g1 phosphorylation, calcium ion influx, and
generation of ROS. This was associated functionally with the
restoration of apoptosis in CTCL cells with adequate FAS
J Wu et al.
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expression. Among CTCL cells with suboptimal FAS expres-
sion, MTX augmented apoptosis. We demonstrated previously
that MTX enhances FAS expression in CTCL cell lines and
leukemic cells by inhibiting methylation of the FAS promoter
and thereby derepressing gene expression (Wu and Wood,
2011). This mechanism of action for MTX appears to result
from inhibition of the synthesis of S-adenosylmethionine, the
main methyl donor used by DNA methyltransferases.
Therefore, either alone or in combination with MTX, c-CBL
knockdown was able to overcome apoptotic resistance in all
CTCL cells tested, regardless of their baseline FAS expression
level.
Our experiments showed that treatment with anti-CD3 and
anti-CD28 antibodies is not required for c-CBL knockdown to
induce apoptosis in CTCL cells. Furthermore, normal T cells
were less sensitive to the pro-apoptotic effects of c-CBL
knockdown than were CTCL cells, suggesting relative
tumor selectivity of this approach. At present, there are no
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Figure 3. c-CBL inhibition in CTCL induces FAS pathway apoptosis and downstream TCR signaling. (a) Flow cytometric histogram of mean fluorescence
intensities (MFIs) shows marked upregulation of cleaved caspase 8 expression (y-axis) induced by c-CBL knockdown in cutaneous T-cell lymphoma (CTCL) lines
and Se´zary syndrome (SS) leukemic blood samples (P1, P2). Bars represent isotype control (Iso), no treatment (C), NS siRNA (NS), MTX (M), c-CBL siRNA (CBL),
and MTX plus c-CBL siRNA (MC). Analogous to the induction of apoptosis (Figure 2), samples with suboptimal baseline FAS death receptor expression (HH, SZ4,
P1 and P2) showed enhanced cleavage of caspase 8 when MTX was combined with c-CBL knockdown. *Po0.05; **Po0.01 relative to NS siRNA controls in
triplicate samples. (b) Grouped immunoblots show marked increase in cleaved caspase 8 but minimal change in cleaved caspase 9 under similar conditions to
those described in a. NS siRNA (N), MTX (M), c-CBL siRNA (C), and MTX plus c-CBL siRNA (MC). (c) (Left) Annexin V/propidium iodide flow cytometric dot plots
show no induction of apoptosis (right two quadrants of each panel) after c-CBL knockdown in the SeAx CTCL line, which lacks the gene for the FAS death receptor.
(A) NS siRNA, (B) MTX, (C) c-CBL siRNA, and (D) MTX plus c-CBL siRNA. Results are representative of triplicate experiments. (Right) Flow cytometric histogram of
MFIs shows marked upregulation of FASL (black bars) but not FAS (white bars) induced by c-CBL knockdown in CTCL line, SeAx. Histogram shows fold change
compared with the ‘‘no treatment’’ control, which is set as 1. FAS levels were always null; hence, the white bars are at the x-axis but are shown slightly larger to be
visible. NS siRNA (NS), MTX (MTX), c-CBL siRNA (CBL), and MTX plus c-CBL siRNA (MþC). **Po0.01 relative to NS siRNA controls in triplicate samples. (d)
Flow cytometric histogram of MFIs shows marked upregulation of phospho-PLC-g1 induced by c-CBL knockdown. Fold change is shown with the isotype control
value set as 1. Bars show no treatment (white), NS siRNA (gray), and c-CBL siRNA (black). *Po0.05; **Po0.01 relative to NS siRNA controls in triplicate samples.
(e) Grouped immunoblots show 2–8-fold increased phospho-PLC-g1/total PLC-g1 ratios (numbers) after c-CBL siRNA knockdown (C) relative to NS siRNA control
(N) set as 1. (e–g) Samples include four CTCL lines (HH, MyLa, SZ4, and Hut-78) and primary tumor cells from three SS patients (P1, P2, and P15). (f) Flow
cytometric histogram of Fluo-4-AM MFIs shows that calcium flux is enhanced by c-CBL knockdown. Fold change is shown with the isotype control value set as 1.
Bars show no treatment (white), NS siRNA (gray), and c-CBL siRNA (black). **Po0.01 relative to NS siRNA controls in triplicate samples. (g) Flow cytometric
histogram of DCFDA MFIs shows that ROS generation is enhanced by c-CBL knockdown. Fold change is shown with the isotype control value set as 1. Bars show
no treatment (white), NS siRNA (gray), and c-CBL siRNA (black). **Po0.01 relative to NS siRNA controls in triplicate samples. (h) In CTCL, the TCR
signaling cascade that normally leads to FASL upregulation is blocked by high c-CBL levels. When c-CBL is inhibited, signaling is restored and FASL increases. This
leads to apoptosis if there is adequate FAS death receptor expression. If FAS is low, then MTX can be used to derepress the FAS promoter, leading to FAS
upregulation and subsequent apoptosis. With this approach, both FAS-high and FAS-low CTCL cells can be killed. CTCL; cutaneous T-cell lymphoma; DCFDA,
20,70-dichlorofluorescein diacetate; MTX, methotrexate; NS siRNA, nonsense short interfering RNA; ROS; reactive oxygen species; TCR, T-cell receptor.
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well-characterized small molecule inhibitors specific for
c-CBL. It is possible that agents affecting other E3 ubiquitin
ligases or the proteasome pathway more broadly might affect
the function of c-CBL. Existing inhibitors such as thalidomide,
lenalidomide, and bortezomib have already shown some
efficacy in CTCL (Jain et al., 2012; Querfeld et al., 2014),
and additional agents are being developed (Lydeard and
Harper, 2010). Our current findings might help explain the
mechanism of action of these drugs in CTCL. Histone
deacetylase inhibitors like tenovin-1 can also indirectly
affect the function of some E3 ubiquitin ligases (Chen et al.,
2007). Our data suggest that an appropriate small molecule
inhibitor of c-CBL, either alone or in combination with MTX,
might provide an effective approach to the treatment of CTCL.
Because MTX’s ability to inhibit DNA methylation is shared by
other folate antagonists, currently approved drugs such as
pralatrexate and pemetrexed might also be of value in this
therapeutic context. Our prior work also showed that
interferon-alpha increased FAS expression in CTCL cells by a
STAT-1-mediated mechanism distinct from the demethylating
action of MTX (Wu et al., 2011) and that their combined
effects on FAS-mediated apoptotic sensitivity were synergistic
(Wu and Wood, 2011). Therefore, addition of this agent to a
multidrug regimen might also prove beneficial in some cases.
In a larger context, our c-CBL knockdown data provide
proof-of-principle that, whether by targeting c-CBL or other
mechanisms, upregulation of FASL is an effective strategy for
killing CTCL tumor cells driven by various proliferative signals
such as the well-documented constitutive activation of NF-kB
(Sors et al., 2008). The physiologic balance between apoptosis
and proliferation in normal T cells is disrupted in CTCL by
constitutive overactivity of both c-CBL and proliferative stimu-
lation. This leads to blocked AICD and unchecked prolifera-
tion. However, when c-CBL is blocked, FASL is upregulated.
AICD can then occur, despite constitutively active prolifera-
tive drivers.
Aside from c-CBL, there are several alternative approaches
that might be exploited to upregulate FASL. It has been
reported that IL-2 plus PKC activators (PMA or bryostatin) that
act downstream of the TCR can induce leukemic CTCL cells to
express FASL and undergo apoptosis ex-vivo (Meech et al.,
2001). Similarly, UV therapy and photodynamic therapy
might also be able to overcome defective TCR signaling by
inducing ROS and upregulating FASL through the JNK–Jun
pathway. This mechanism for FASL upregulation has been
reported in squamous cell carcinomas (Ahmad et al., 2000; Ali
et al., 2002; Furre et al., 2006). However, AP1 transcription
factors containing c-Jun repress FAS expression. Therefore,
concomitant therapy with MTX or other DNA methylation
inhibitors might be important for ensuring the presence of
sufficient FAS to interact with FASL and trigger apoptosis. In
fact, our recent studies show that PDT induces FAS ligand in
CTCL and that MTXþ PDT induces both FAS and FAS ligand,
resulting in significantly enhanced apoptosis relative to PDT
alone (Salva et al., 2014). Finally, it has been shown that
nonsteroidal anti-inflammatory agents such as diclofenac can
promote extrinsic pathway apoptosis by decreasing the inhibi-
tory factor c-FLIP (Braun et al., 2012).
MATERIALS AND METHODS
CTCL cell lines, SS blood specimens, and MF/SS skin lesions
Human CTCL lines derived from patients with MF (MyLa, HH) or SS
(SZ4, Hut-78, SeAx) were studied. All have been described previously
(Wu et al., 2009; Wu and Wood, 2011). Cells were cultured under
standard conditions and harvested by centrifugation.
All clinical samples were obtained with institutional review board
approval. All patients gave written informed consent, and all
protocols adhered to the Declaration of Helsinki principles. BMCs
were obtained from 15 SS patients (P1-P15). This included 6 men
and 9 women: 2 stage IIIB, 12 stage IVA, and 1 stage IVB. In all cases,
the majority of cells were tumor cells as assessed by V-beta TCR
antibodies, CD4þ 26 phenotype, and/or Se´zary preparations
(11 in the 86–99% range; 4 in the 61–71% range). Lesional skin
biopsies were obtained from 8 men and 7 women: 10 patch/plaque
MF (2 stage IA, 5 stage IB, and 3 stage IIB), 3 tumor MF (all stage IIB),
and 2 SS (stages IVA and IVB). Samples were obtained prior to or 1
month off therapy. Multispectral image analysis using the Nuance
computerized microscope system was employed for quantitative
measurement of in-situ c-CBL protein expression in these biopsies
as described previously by us (Wu et al., 2014).
In some experiments, cells were stimulated with a combination of
monoclonal antibodies directed against CD3 (OKT3; eBioscience;
San Diego, CA) and CD28 (CD28.2; BD Biosciences; San Jose, CA)
prior to other interventions. Cell culture plates were pre-coated with
anti-CD3 antibody (30mg ml 1) for 24 hours at 4 1C. Cells then were
stimulated with plate-bound anti-CD3, soluble anti-CD28 (3mg ml 1),
and goat anti-mouse (2.5mg ml 1) antibodies (BD Biosciences) for 24
hours. In some experiments, cells were treated with MTX, which was
obtained from MP Biomedicals (Santa Ana, CA), dissolved in DMSO,
and diluted to 10mM in culture medium.
Flow cytometry
Expression of FAS, FASL, phospho-PLC-g1, and cleaved caspase 8
was assessed by flow cytometry. Cells were stained with FITC-
conjugated antibody against FAS/CD95 (DX2), biotin-conjugated
(NOK-1) or unconjugated (G247-4) antibody against FAS ligand/
CD178 (BD Biosciences), anti-phospho-PLC-g1 (Tyr783), and anti-
cleaved caspase-8 (18C8) (Cell Signaling, Beverly, MA). Isotype-
matched mAbs of irrelevant specificity were used as negative
controls. Briefly, 2 105 lymphoid cells were washed twice with
phosphate-buffered saline (PBS) and blocked with 1:10 normal goat
serum in PBS for 20 minutes. For phospho-PLC-g1 and cleaved
caspase 8 detection, cells were fixed by Cytofix Buffer and
permeablized by Perm Buffer III (BD Biosciences). Cells were then
immunostained for 30 minutes at room temperature and washed
twice with PBS. If needed, secondary staining with FITC-conjugated
avidin or goat anti-mouse IgG (BD Biosciences) was then performed,
followed by further washing. Cells were then resuspended in FACS
buffer (2% BSA in PBS) and analyzed with a FACSCalibur bench top
flow cytometer (BD Biosciences). Data analysis was performed using
FlowJo software (Treestar, Ashland, OR).
For Annexin V/PI apoptosis analysis, control and treated cells were
collected, washed with PBS and then resuspended in 100ml binding
buffer (0.1 M Hepes, pH 7.4; 1.4 M NaCl; 25 mM CaCl2), and stained
with FITC-conjugated Annexin V and PI (BD Biosciences) as per
vendor’s guidelines. After staining, flow cytometric analysis was
performed as described above. Annexin V single-positive cells were
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interpreted as early apoptotic cells (right lower quadrant of dot plots).
Annexin V/PI double-positive cells were interpreted as late apoptotic
cells (right upper quadrant of dot plots).
Calcium mobilization and ROS assays
To assess calcium ion flux, cells were stained with Fluo-4-AM dye,
and, to assess the generation of ROS, cells were stained with DCFDA
and subjected to flow cytometric analysis as described above. For
Fluo-4-AM staining, cells were washed and resuspended in PBS, and
Fluo-4-AM was added to a final concentration of 1mM. Cells then
were incubated in room temperature for 1 hour. For DCFDA staining,
DCFDA was directly added to 2 ml of cell culture to the final
concentration of 5mM and incubated at 37 1C for 30 minutes. Stained
cells were washed and analyzed by flow cytometry.
Immunoblotting
Following treatments, cells were washed with ice-cold PBS and lysed
with RIPA buffer. For immunoblot analysis, 30mg of each protein
sample was subjected to SDS-PAGE and transferred onto a nitrocel-
lulose membrane. Blots were exposed to anti-c-CBL (D4E10), cleaved
caspase 8 (18C8), caspase 9 (C9), PLC-g1 (D9H10) and phospho-PLC-
g1 (Tyr 783) primary antibodies (Cell Signaling; Beverly, MA), and
horseradish peroxidase-conjugated appropriate secondary antibodies
(Cell Signaling; Danvers, MA), followed by enhanced chemilumines-
cent detection (Thermo Fisher Scientific, Rockford, IL) using the
Fotodyne digital imaging system (Fotodyne, Hartland, WI). Loading
control antibody was anti-GAPDH (D16H11; Cell Signaling; Beverly,
MA). Numbers in immunoblot lanes represent scanning densitometry
relative to controls.
Quantitative real-time reverse-transcriptase–PCR
RNA was isolated with Trizol reagent (Life Technologies, Grand
Island, NY), treated with DNase (Promega, Madison, WI), and first-
strand complementary DNA created with M-MLV reverse transcrip-
tase (Promega) according to the vendor’s protocol. QRT-PCR was
performed with SYBR Green PCR Master Mix (Life Technologies).
Relative c-CBL messenger RNA expression was calculated using the
DDCT method with GAPDH as an endogenous control. The primer
sequences and conditions for QRT-PCR are shown below:
Sequence (50-30) Length Tm Location
Fw c-CBL
primer
GTGATCCCTGGACAGGAAGA 20 60.0 1959–1979
Rev c-CBL
primer
CATTGGCAGATGAGGAAGGT 20 62.4 2156–2176
Fw GAPDH
primer
TGTGGGCATCAATGGATTTGG 21 60.9 231–251
Rev GAPDH
primer
ACACCATGTATTCCGGGTCAAT 22 61.4 346–325
Abbreviations: Fw, forward; Rev, reverse.
c-CBL knockdown
Knockdown of c-CBL was performed using siRNA technology. Four
pooled siRNA oligos targeting c-CBL (#1027416) or nonspecific
siRNAs (#1027280) were obtained from Qiagen (Valencia, CA) and
were transfected into cells by electroporation using the Nucleofector
device and the L kit (Lonza, Basel, Switzerland). Briefly, cells were
cultured under normal conditions to the log-growth stage, 3 106 cells
were centrifuged and resuspended in 100ml of transfection solution L,
and siRNA was added to a final concentration of 1mM and transfected
using pre-installed program X-001 in Nucleofector. The c-CBL siRNA
sequences were as follows: 50-CCCGCCGAACTCTCTCAGATA-30,
50-CCGTACTATCTTGTCAAGATA-30, 50-CCCATACTTCGTATTCTTA
AA-30, and 50-CTGGCGCTAAAGAATAGCCCA-30. Cells were cultured
for 4 days prior to detection or further processing. Controls included
isotype antibody, no treatment, and nonsense siRNA.
Statistics
Statistical analysis was performed using Student’s t-test. A
P-valueo0.05 was considered statistically significant. Error bars in
histograms show standard deviations of triplicate measurements.
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